To investigate whether the combined effect of venetoclax and VPA was specific to AML cells, we examined K562 cells, a chronic myeloid leukemia (CML) cell line expressing the BCR-ABL fusion protein due to t(9;22) chromosome translocation. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.